G.d. Searle & Company

Pharmacia Corporation

Imago Biosciences, Inc.

Monsanto Company

Bioenergenix LLC

Other

Northern Illinois University

Neosinus Health Inc

Oxalurx, Inc.

Beryllium Discovery Corp.

Mosanto Company

Monsanto Company of St. Louis

Pharmacia Corporation (monsanto Corporation)

Anovia Biosciences, Inc.

Emerald Biostructures, Incorporated

Michael John Clare

John Jeffrey Talley

Michael L Vazquez

Daniel P Getman

Robert M Heintz

Kathryn L Reed

Richard M Weier

Gunnar J Hanson

John Michael McCall

Michael A Stealey

Mark Andrew Russell

Lifeng Geng

Richard A Partis

Ish K Khanna

Richard A Mueller

Gary A DeCrescenzo

John Nicholas Freskos

Ko-Chung Lin

Suzanne S Metz

He Huang

Francis J Koszyk

Barbara B Chen

Alan Frank Gasiecki

Hugh Young Rienhoff, Jr

Shuyuan Liao

Joyce Zuowu Crich

Donald W Hansen, Jr

Paul Waddell Collins

Xiangdong Xu

Thomas Dale Penning

Barnett S Pitzele

Donna Lee Romero

Nizal S Chandrakumar

Shashidhar N Rao

Yi Yu

Daniel L Flynn

Matthew James Graneto

Thomas Edward Rogers

Michael S South

Shaun Raj Selness

Rajesh Devraj

Bipinchandra N Desai

Susan J Hartmann

Cathleen Elizabeth Hanau

Robert W Hamilton

Ashok Anantanarayan

Thao D Perry

Timothy J Hagen

Deborah E Bertenshaw

Robert Alan Chrusciel

Cassandra Celatka

Amy E Tapper

Julie M Miyashiro

Donald J Rogier, Jr

Richard A Haack

Stephen Hermann Docter

John McKearn

Hwang-Fun Lu

Ashok S Naraian

Stevan Wakefield Djuric

James W Malecha

Stella S Yu

Peter Gerrard Ruminski

Chi-Dean Liang

Daniel R Pilipauskas

Michael Hepperle

Donald Joseph Rogier, Jr

Joseph Gerace Rico

Eric T Sun

Helen Y Chen

Stephen C Houdek

Win Naing

Michael E Hepperle

Syaulan Yang

Donna M Iula

Srinivasan Raj Nagarajan

Michael B Tollefson

Mehmet Kahraman

Patrick J Lennon

Bruce C Hamper

Arija A Bergmanis

Subo Liao

Thomas Dale Owen

Kashif Mazhar

Richard John Lindmark

John Walker

Magda R Pugh

Dominique Bonafoux

Ayman Kabakibi

Scott B Mohler

Serge G Wolfson

Theresa R Fletcher

Jing Li

Balekudru Devadas

E Ann Hallinan

Juan Du

Michael F Rafferty

Renee Huff

Ronggang Liu

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

Compounds and methods for treating oxalate-related diseases

Devices and methods for delivering fluid from a container to the nasal cavity. The device includes a selector and a nozzle that are connected together and rotatable relative to each other. The device includes a curve to overcome anatomical barriers and one or more openings to provide for effective distribution when delivering the fluid to the nasal cavity. The selector includes an opening that aligns with a corresponding opening in a container that holds the fluid. The nozzle includes a first passage with one or more openings on a first lateral side, and a second passage with one or more openings on an opposing second lateral side. The selector and nozzle can be positioned at a first and second rotational positions to selectively deliver the fluid through the first and second passages to the nasal cavity.

Devices and methods for delivering fluid to a nasal cavity

This invention relates to LOX enzyme-inhibiting compounds in accordance with Formula I or Formula II, or a pharmaceutically acceptable salt or hydrate thereof: and pharmaceutical compositions comprising the compounds. Such compounds and compositions can be useful in treating a variety of conditions, diseases, and disorders including, but not limited to, fibrotic disorders, proliferative disorders, cardiovascular disorders, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, and neurological and neuropsychiatric conditions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

LOX enzyme inhibiting methods and compositions

The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.

KDM1A inhibitors for the treatment of disease

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Disclosed is a cloud-based resource and information tracking system for medical patients and healthcare providers. The cloud-based software system integrates all or many sources of patient medical and health information, updates the information in near real-time, and makes the data available to member(s) of the patient's healthcare team securely.

Automated pill dispenser

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Heterocyclic compounds for the inhibition of PASK

Growing community of inventors

Sylva, NC, United States of America

Michael John Clare